We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

117 hedge funds and large institutions have $177M invested in Lyell Immunopharma in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0.11% less ownership

Funds ownership: 2.62% → 2.51% (-0.11%)

3% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 32

5% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 20

2% less funds holding

Funds holding: 119 → 117 (-2)

9% less capital invested

Capital invested by funds: $194M → $177M (-$17.4M)

Holders
117
Holders Change
-2
Holders Change %
-1.68%
% of All Funds
1.68%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
19
Increased
31
Reduced
32
Closed
20
Calls
$39K
Puts
–
Net Calls
+$39K
Net Calls Change
+$36K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$1.88M
2
HF
HRT Financial
New York
+$836K
3
Goldman Sachs
Goldman Sachs
New York
+$710K
4
GCP
GSA Capital Partners
United Kingdom
+$484K
5
BlackRock
BlackRock
New York
+$370K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$4.89M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.51M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$837K
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$764K
5
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$555K
Name Holding Trade Value Shares
Change 		Change in
Stake
AB
101
Amalgamated Bank
New York
$8K – – –
SO
102
STRS Ohio
Ohio
$7.04K – – –
PD
103
Point72 (DIFC)
United Arab Emirates
$4.9K +$5.23K +178 New
GRP
104
Global Retirement Partners
California
$4.27K +$4.55K +155 New
Carson Wealth (CWM LLC)
105
Carson Wealth (CWM LLC)
Nebraska
$4K +$4.17K +142 +888%
Citadel Advisors
106
Citadel Advisors
Florida
$2.45K -$402K -13,697 -99%
US Bancorp
107
US Bancorp
Minnesota
$1.61K – – –
Daiwa Securities Group
108
Daiwa Securities Group
Japan
$1K – – –
SCM
109
Sterling Capital Management
North Carolina
$704 +$764 +26 New
TWD
110
True Wealth Design
Ohio
$432 +$470 +16 New
SAM
111
Smartleaf Asset Management
Massachusetts
$403 +$382 +13 New
CPA
112
Capital Performance Advisors
California
$236 +$264 +9 New
Nisa Investment Advisors
113
Nisa Investment Advisors
Missouri
$164 -$470 -16 -73%
Group One Trading
114
Group One Trading
Illinois
$138 – – –
AAP
115
Arax Advisory Partners
Colorado
$132 – – –
Massachusetts Financial Services
116
Massachusetts Financial Services
Massachusetts
– -$837K -28,866 Closed
Wellington Management Group
117
Wellington Management Group
Massachusetts
– -$533K -18,384 Closed
American Century Companies
118
American Century Companies
Missouri
– -$405K -13,971 Closed
Franklin Resources
119
Franklin Resources
California
– -$143K -4,933 Closed
XT
120
XTX Topco
Cayman Islands
– -$102K -3,509 Closed
Mercer Global Advisors
121
Mercer Global Advisors
Colorado
– -$58.6K -2,020 Closed
Jacobs Levy Equity Management
122
Jacobs Levy Equity Management
New Jersey
– -$45.2K -1,559 Closed
WP
123
Woodline Partners
California
– -$30.1K -1,037 Closed
VPIM
124
Vanguard Personalized Indexing Management
California
– -$27.1K -934 Closed
BFG
125
Bleakley Financial Group
New Jersey
– -$26.7K -921 Closed
2 3 4
5
6

LYEL Hedge Fund Activity: Q3 2024 in Review

117 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q3 2024, worth a combined $177M — down 9% from $194M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of LYEL and 19 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 31 added.

The largest buyer was Morgan Stanley, adding an estimated $1.88M. The largest seller was Vanguard Group, cutting an estimated $4.89M.

  • 117 institutional investors held Lyell Immunopharma (LYEL) as of Q3 2024, down from 119 in Q2 2024.
  • Funds reported $177M of Lyell Immunopharma stock for Q3 2024, down 9% quarter-over-quarter.
  • 19 funds opened new Lyell Immunopharma positions in Q3 2024 and 20 closed out, a net change of -1 holder.
  • The largest Lyell Immunopharma buyer in Q3 2024 was Morgan Stanley, an estimated $1.88M added.
  • The largest Lyell Immunopharma seller in Q3 2024 was Vanguard Group, an estimated $4.89M sold.

Based on aggregated 13F filings for Q3 2024.